IFNG and melanoma: To our knowledge, DONIMI is the first neoadjuvant immunotherapy trial that used a biomarker to allocate therapy in melanoma by prospectively testing an IFN-γ signature gene expression score to allocate patients with stage III melanoma to different combinations of neoadjuvant ICB with domatinostat.